Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
6/2/25 | Pfizer (PFE) | Disitamab Vedotin for Gastric Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
6/2/25 | Daiichi (4568) | Enhertu for HER2+ Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
6/2/25 | GSK (GSK) | Jemperli for Ovarian Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
6/2/25 | Corcept Therapeutics (CORT) | Relacorilant for Ovarian Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
6/2/25 | AstraZeneca (AZN) | Tagrisso for Non-Small Cell Lung Cancer (NSCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
04/01/2025 | Subscribers Only | Subscribers Only | Company - Divestment/Spinoff |
04/24/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
05/12/2025 | Subscribers Only | Subscribers Only | Trial Data - Other |
05/20/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
05/22/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |